Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.48 |
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | BID | P55957 | 2/20 | 0.48 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582598 | 0.91 | MCHR1 (0.66) | MCHR1HTR2CLCKCSF1RABL1 | |
| SCHEMBL5582951 | 0.87 | MCHR1 (0.63) | MCHR1HTR2CRAB9A | |
| SCHEMBL5583052 | 0.86 | MCHR1 (0.56) | MCHR1HTR2CLCKCSF1RABL1 | |
| SCHEMBL5582952 | 0.86 | MCHR1 (0.61) | MCHR1HTR2C | |
| SCHEMBL5583001 | 0.86 | MCHR1 (0.60) | MCHR1HTR2C | |
| SCHEMBL5582521 | 0.85 | MCHR1 (0.64) | MCHR1HTR2CMAPK14RAB9A | |
| SCHEMBL5582730 | 0.84 | MCHR1 (0.64) | MCHR1HTR2CBIDBCL2A1 | |
| SCHEMBL5582939 | 0.83 | MCHR1 (0.57) | MCHR1HTR2CLCKCSF1RABL1 | |
| SCHEMBL5582523 | 0.82 | MCHR1 (0.55) | MCHR1HTR2CLCKCSF1RABL1 | |
| SCHEMBL5582590 | 0.80 | MCHR1 (0.58) | MCHR1ABL1BIDBCL2A1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885LCK 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.